Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (2022 - 2025)

InMed Pharmaceuticals' Shares Outstanding history spans 4 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 287.24% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 287.24%, while the annual FY2025 figure was $2.0 million, 349.01% up from the prior year.
  • Shares Outstanding reached $2.8 million in Q4 2025 per INM's latest filing, up from $2.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $5.7 million in Q4 2023 to a low of $166370.0 in Q2 2023.
  • Average Shares Outstanding over 4 years is $1.7 million, with a median of $965669.0 recorded in 2024.
  • Peak YoY movement for Shares Outstanding: soared 155.52% in 2024, then soared 349.01% in 2025.
  • A 4-year view of Shares Outstanding shows it stood at $571354.0 in 2022, then crashed by 50.4% to $283399.0 in 2023, then skyrocketed by 155.52% to $724152.0 in 2024, then skyrocketed by 287.24% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Shares Outstanding are $2.8 million (Q4 2025), $2.6 million (Q3 2025), and $2.0 million (Q2 2025).